Jaguar Health announced that the company will effect a reverse stock split of its issued and outstanding voting common stock at an exchange ratio of 1-for-60, on Thursday, May 23 in order to support the company’s compliance with Nasdaq’s listing standards. The company’s common stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol “JAGX“. The new CUSIP number for the company’s common stock following the reverse stock split is 47010C805. “Jaguar’s board of directors has determined that effecting a reverse stock split at this time will, in addition to supporting the Company’s compliance with Nasdaq’s listing standards, provide Jaguar with the opportunity to achieve a share price and outstanding share count that is more attractive to institutional investors,” said Lisa Conte, Jaguar’s president and CEO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health reports Q1 EPS (6c) vs. ($2.39) last year
- Jaguar Health announces submission of clinical trial applications for crofelemer
- Jaguar Health establishes INAD file with FDA’s CVM for crofelemer
- Jaguar Health files $75M mixed securities shelf
- Biotech Alert: Searches spiking for these stocks today